Scientific deep-dive

Ozempic Without Diabetes: Off-Label Use for Weight Loss Evidence Review

Ozempic is FDA-approved only for type 2 diabetes — off-label for weight loss is legal under 21 USC 396 but rarely insurance-covered. Wegovy is the on-label equivalent (same semaglutide, 2.4 mg vs 2.0 mg max). SELECT trial extends CV safety to non-diabetic obese adults.

By Eli Marsden · Founding Editor
Editorially reviewed (not clinically reviewed) · How we verify contentLast reviewed
12 min read·10 citations

This off-label-prescribing clarifier is part of Weight Loss Rankings’ living editorial database — 300+ research articles and 190+ clinically-reviewed GLP-1 telehealth providers, sourced only from FDA prescribing information on DailyMed and peer-reviewed PubMed literature.

Ozempic is FDA-approved only for type 2 diabetes glycemic control plus cardiovascular risk reduction in adults with T2D and established cardiovascular disease. Using Ozempic for weight loss in adults who do not have type 2 diabetes is off-label prescribing: legal under the Practice of Medicine clause of the Federal Food, Drug, and Cosmetic Act, but not what the FDA label authorizes, not typically insurance-covered without a T2D diagnosis, and not the most clinically appropriate option when an FDA-approved equivalent exists. The on-label equivalent is Wegovy — same semaglutide molecule, dosed higher (2.4 mg vs 2.0 mg), approved for chronic weight management.

The honest answer

Ozempic is FDA-approved only for type 2 diabetes — using it for weight loss without diabetes is OFF-LABEL prescribing. Off-label use is legal under the Practice of Medicine clause (21 USC 396) but typically not insurance-covered without a T2D diagnosis. The FDA-approved equivalent for weight loss without diabetes is Wegovy (same semaglutide molecule at a higher 2.4 mg dose). The SELECT trial (Lincoff 2023, PMID 37952131) extends the cardiovascular safety record to non-diabetic obese adults.

Is Ozempic FDA-approved for weight loss without diabetes? (No)

The Ozempic FDA-approved prescribing information, Section 1 Indications and Usage, lists two indications[1]:

  1. Adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus.
  2. Reduction in the risk of major adverse cardiovascular events (cardiovascular death, nonfatal myocardial infarction, nonfatal stroke) in adults with type 2 diabetes mellitus and established cardiovascular disease.

Both labeled indications require a T2D diagnosis. The Ozempic label does not include a chronic-weight-management indication; it does not include a weight-loss indication for adults with obesity or overweight without T2D; it does not include any obesity-only indication. The FDA evaluated Ozempic against the T2D evidence base (SUSTAIN program, Sorli 2017 PMID 28110911[4]; SUSTAIN-6, Marso 2016 PMID 27633186[5]) and approved it for the T2D population.

Weight loss is a documented secondary effect of Ozempic in the SUSTAIN trials — mean -3.7 to -4.5 kg at 30 weeks on 0.5 mg or 1.0 mg weekly in T2D[4] — but a secondary pharmacodynamic effect in the labeled population is not the same as an approved indication. A drug that produces weight loss in the course of treating diabetes is not, by that fact alone, an FDA-approved weight-loss drug.

For the broader question of how Ozempic is sold and distributed (and why “over-the-counter Ozempic” is a category that does not exist), see Is Ozempic available over the counter?

Wegovy is the on-label semaglutide for weight loss

The pharmacologic equivalent of Ozempic for chronic weight management is Wegovy. Same molecule (semaglutide), same manufacturer (Novo Nordisk), same once-weekly subcutaneous administration. The differences are entirely regulatory and dose-related[2]:

AttributeOzempicWegovy
Active ingredientSemaglutideSemaglutide
FDA-approved indicationType 2 diabetes glycemic control; MACE reduction in T2D + CV diseaseChronic weight management; MACE reduction in CV disease + obesity/overweight
FDA approval year (current indication)2017 (T2D); 2020 (CV in T2D)2021 (weight); 2024 (CV in obesity)
Dose ladder0.25 / 0.5 / 1.0 / 2.0 mg once weekly0.25 / 0.5 / 1.0 / 1.7 / 2.4 mg once weekly
Maximum approved dose2.0 mg once weekly2.4 mg once weekly
Pivotal obesity trialNone at the 2.0 mg dose in a non-diabetic obese cohortSTEP-1 (Wilding 2021, PMID 33567185)
Trial weight-loss magnitude-3.7 to -4.5 kg at 30 wk in T2D (SUSTAIN-1, 0.5/1.0 mg)-14.9% body weight at 68 wk (STEP-1, 2.4 mg)

Two regulatory facts deserve emphasis. First, the Ozempic 2.0 mg dose has never been tested in a pivotal randomized controlled trial against placebo in a non-diabetic obese cohort. The weight-loss magnitude data for Ozempic comes from T2D trials at doses of 0.5 mg and 1.0 mg, with the 2.0 mg dose added via the SUSTAIN FORTE study in T2D. Second, the headline -14.9% body-weight number from STEP-1[3] is for semaglutide 2.4 mg — the Wegovy dose — not for any Ozempic dose. Off-label Ozempic prescribers who quote the STEP-1 magnitude as the expected outcome are quoting the Wegovy dose, not the Ozempic dose.

Magnitude comparison

Semaglutide weight-loss magnitude by dose and trial population. The 14.9% STEP-1 magnitude is for semaglutide 2.4 mg (the Wegovy dose) in adults with obesity but no T2D. The Ozempic-dose data comes from SUSTAIN-1, a 30-week T2D trial at 0.5 mg and 1.0 mg weekly — no comparable obesity pivotal exists at the Ozempic 2.0 mg maximum.[3][4]

  • STEP-1 semaglutide 2.4 mg — % body weight at 68 wk14.9 % TBWL
    Wegovy dose, adults with obesity, no T2D
  • STEP-1 placebo — % body weight at 68 wk2.4 % TBWL
    diet + lifestyle baseline, no T2D
  • SUSTAIN-1 semaglutide 1.0 mg — kg at 30 wk in T2D4.5 kg loss
    Ozempic dose, T2D population
  • SUSTAIN-1 semaglutide 0.5 mg — kg at 30 wk in T2D3.7 kg loss
    Ozempic dose, T2D population
Semaglutide weight-loss magnitude by dose and trial population. The 14.9% STEP-1 magnitude is for semaglutide 2.4 mg (the Wegovy dose) in adults with obesity but no T2D. The Ozempic-dose data comes from SUSTAIN-1, a 30-week T2D trial at 0.5 mg and 1.0 mg weekly — no comparable obesity pivotal exists at the Ozempic 2.0 mg maximum.

For the head-to-head pharmacologic, dose, indication, and pricing comparison between the two products in detail, see Wegovy vs Ozempic: same molecule, different labels and the disambiguation page Is Wegovy the same as semaglutide?

Why prescribers off-label Ozempic vs prescribing Wegovy

If the on-label option exists and is dosed higher for weight loss, why does off-label Ozempic prescribing for weight management happen at the rates documented in the literature[7][8]? Four practical drivers, in rough order of magnitude:

1. Cost and insurance reality

Ozempic is more commonly covered by US commercial insurance than Wegovy. T2D coverage is more universally mandated across formularies than chronic weight management coverage, which many plans exclude outright. A patient with even borderline T2D (or pre-diabetes progressing toward T2D) can frequently obtain insured Ozempic with a standard prior authorization, while the same patient’s Wegovy prescription for weight management triggers anti-obesity-medication coverage exclusions, BMI documentation requirements, step therapy, and out-of-pocket costs that can exceed $1,000/month at retail.

For self-pay patients, both products list at $499/month through Novo Nordisk’s NovoCare Pharmacy direct-pay channel, but at retail list (WAC) both products approach $1,349/month. The cost gap is primarily a coverage gap, not a list-price gap. For the practical cash-pay landscape across the GLP-1 category, see Cheapest GLP-1 without insurance: buyer guide.

2. Supply and formulary positioning

Through 2023 and into 2024 the FDA drug-shortage list included both semaglutide products, with Wegovy supply lagging Ozempic supply across many regional markets. The Wegovy initiation doses (0.25 mg and 0.5 mg) were repeatedly the hardest to obtain; some prescribers treated Ozempic as a workaround when Wegovy initiation pens were unavailable. The FDA formally declared the semaglutide shortage resolved in February 2025, removing this rationale, but the prescribing pattern set during the shortage has not fully normalized.

3. Prescriber familiarity

Ozempic was FDA-approved in 2017; Wegovy in 2021. Many primary care and endocrinology clinicians have multi-year prescribing experience with Ozempic across thousands of patient-encounters, vs more limited Wegovy familiarity. Defaulting to the more-familiar drug, even at a slightly lower dose ceiling, is a recognized clinical behavior pattern reviewed by Schmitz and Aronne 2023[9]in the context of anti-obesity medication uptake.

4. Pharmacy-level substitution dynamics

At certain points during the 2023-2024 shortage, some pharmacies substituted Ozempic for Wegovy prescriptions at the same dose (where overlapping — 0.25, 0.5, 1.0 mg). Substitution in either direction across distinct NDA approvals is not a standard pharmacist substitution and should not occur, but it did in practice, contributing to the blurring between the two products in the patient-facing prescription record.

None of these four drivers is a clinical reason to prefer Ozempic over Wegovy when the goal is weight management. Each is a real-world access or workflow reason. The clinical case for Wegovy at 2.4 mg over Ozempic at 2.0 mg in a non-diabetic patient with obesity is straightforward: the on-label indication, the higher dose ceiling, the STEP-1 obesity-population trial evidence base, and the SELECT cardiovascular extension[6].

Off-label prescribing is legal in the United States. The statutory source is Section 396 of the Federal Food, Drug, and Cosmetic Act (codified at 21 USC §396), the “Practice of Medicine” clause[10]. The clause explicitly disclaims FDA authority to limit how a licensed clinician prescribes an FDA-approved drug within the practice of medicine:

“Nothing in this Act shall be construed to limit or interfere with the authority of a healthcare practitioner to prescribe or administer any legally marketed device to a patient for any condition or disease within a legitimate health care practitioner- patient relationship.”

Although the cited statutory text addresses devices, the well-established corresponding doctrine for drugs is the same: the FDA regulates manufacturer marketing, labeling, and approved indications, but does not regulate the practice of medicine. A licensed prescriber may, within the standard of care and with informed patient consent, prescribe an FDA-approved drug for a condition or population not listed on the FDA-approved label. This is what “off-label prescribing” means.

Three boundaries deserve emphasis:

  • Manufacturers cannot promote off-label uses. The 21 USC 396 protection covers the clinician, not the manufacturer. Novo Nordisk cannot legally promote Ozempic for weight management. That is why Novo Nordisk’s weight-loss marketing channels (NovoCare Wegovy program, weight-management-focused HCP materials) reference Wegovy, not Ozempic. A clinician’s off-label use is permissible; a manufacturer’s off-label promotion is not.
  • Off-label prescribing must remain within the standard of care. The clinician is professionally accountable for the prescribing decision under state medical-board licensure and malpractice standards. Off-label prescribing supported by published evidence (e.g., off-label Ozempic for weight loss, supported by SUSTAIN weight data + indirect SELECT extrapolation + Wegovy STEP data for the same molecule at a higher dose) is on solid standard-of- care ground. Off-label prescribing for a use with no published evidence base is not.
  • Insurance is not obligated to cover off-label prescribing. The legal permission to prescribe off-label is separate from any obligation on a payer to cover the drug at the off-label use. Most commercial insurance plans and Medicare Part D plans require the on-label indication be present for coverage, with well-defined exceptions for off-label uses recognized in the published compendia (e.g., AHFS-DI, DRUGDEX). Off-label Ozempic for weight loss in a patient with no T2D diagnosis is rarely a compendium-recognized off-label use, and is therefore rarely covered.

Insurance + cost reality

For a patient considering off-label Ozempic for weight loss, the coverage map looks like this in 2026:

  • Commercial insurance, no T2D diagnosis, weight-loss intent: Most plans deny. Off-label Ozempic for weight loss without T2D is not a compendium-recognized indication. Pharmacy benefit managers (PBMs) routinely require a T2D ICD-10 code (E11.x) plus HbA1c documentation to approve Ozempic. Some patients obtain coverage by virtue of a pre-diabetes or insulin resistance picture that satisfies prior authorization, but this is a gray zone that varies by plan.
  • Commercial insurance, T2D diagnosis present: Most plans cover Ozempic. Coverage is the indication-aligned path, not the workaround path. Weight loss is a documented secondary benefit in the T2D-treatment context.
  • Medicare Part D, no T2D: Not covered. Medicare does not cover anti-obesity medications by statute (the Medicare Prescription Drug, Improvement, and Modernization Act of 2003 excludes drugs “used for anorexia, weight loss, or weight gain”). Off-label Ozempic prescribed for weight loss in a Medicare patient without T2D is not reimbursable through Part D.
  • Medicare Part D, T2D present: Covered, with standard formulary tiering. Weight loss is again a secondary benefit.
  • Cash-pay self-pay: Novo Nordisk’s NovoCare Pharmacy direct-pay channel lists Ozempic at $499/month for self-pay patients, the same nominal price as Wegovy at NovoCare. The same patient cash-paying for weight loss can fill either product; the regulatory distinction matters less in a pure cash transaction, but the clinical rationale for picking the on-label higher-dose Wegovy over the off-label lower-dose Ozempic still applies.
  • Medicaid: Coverage varies by state. State Medicaid programs frequently cover Ozempic for T2D but exclude it for off-label weight loss. The 50-state Medicaid coverage map is documented across the WLR state-by-state research series.

For locating an actual prescriber who works within these coverage constraints, see How to find a GLP-1 prescriber near you.

Safety extrapolation: SELECT trial extends the record

The single most important safety question for off-label Ozempic in non-diabetic adults is whether the safety profile established in the T2D pivotal program (SUSTAIN-1 through SUSTAIN-10, SUSTAIN-6 for CV outcomes) extends to a population the FDA Ozempic label was not designed to cover. The answer, as of 2024 onward, is yes — but the extension is through the Wegovy trial, not the Ozempic trial.

SELECT (Lincoff 2023, PMID 37952131)[6] randomized 17,604 adults aged 45+ with established cardiovascular disease and overweight or obesity but without diabetes to semaglutide 2.4 mg weekly or placebo, with a median follow-up of 39.8 months. The primary MACE composite (CV death, nonfatal MI, nonfatal stroke) occurred in 6.5% of the semaglutide group vs 8.0% of placebo (HR 0.80, 95% CI 0.72-0.90, p<0.001). The safety profile in SELECT was consistent with the semaglutide prior evidence base: gastrointestinal events (nausea, vomiting, diarrhea, constipation, abdominal pain) drove the elevated adverse-event rate in the semaglutide arm; serious adverse events were not increased; specific safety signals previously monitored (acute pancreatitis, acute gallbladder events, acute kidney injury secondary to GI losses, diabetic retinopathy complications) did not show new patterns in the non-diabetic population.

SELECT used Wegovy 2.4 mg, not Ozempic 2.0 mg, so the extrapolation has three layers worth naming explicitly:

  • Same molecule. Semaglutide is the same active ingredient in Ozempic and Wegovy. The pharmacodynamic and pharmacokinetic profile at a given dose is identical regardless of which pen the drug comes from.
  • Higher dose, harder test. SELECT tested 2.4 mg weekly. The Ozempic maximum is 2.0 mg weekly — a lower systemic exposure. Safety signals that did not appear at 2.4 mg for a median of 39.8 months in 17,604 non-diabetic adults are highly unlikely to appear at 2.0 mg in the same population.
  • Population overlap. SELECT enrolled non-diabetic adults with overweight or obesity plus cardiovascular disease — effectively the patient population most clinicians would reach for off-label Ozempic to treat. The clinical decision is supported by the SELECT data even though the SELECT-tested product is Wegovy.

Two practical caveats. First, SELECT enrolled adults with established CV disease; the safety record extends most cleanly to that population, not to younger non-diabetic adults with obesity but without CV disease (though the STEP-1 obesity trial covers that group[3]). Second, SELECT enrolled adults aged 45+; pediatric and adolescent extrapolation is not supported by SELECT.

For the side-effect picture specifically — what the GI adverse-event rates look like in practice, including data on whether non-diabetic patients tolerate semaglutide differently than T2D patients — see Full GLP-1 medication list reference.

When to switch from off-label Ozempic to on-label Wegovy

For most non-diabetic adults using off-label Ozempic for weight loss, the clinical question is when (not whether) to migrate to the on-label Wegovy product. Five common triggers:

  1. Weight-loss plateau on Ozempic 1.0 or 2.0 mg with target still above goal. The Ozempic dose ceiling is 2.0 mg; Wegovy adds a 2.4 mg step that has documented additional weight-loss efficacy in the STEP-1 pivotal population[3]. Plateauing at 2.0 mg with substantial weight still to lose is the canonical trigger to migrate.
  2. Acquiring established cardiovascular disease (myocardial infarction, stroke, peripheral arterial disease, coronary revascularization). The Wegovy CV indication based on SELECT[6] is now a compendium-recognized indication; Medicare Part D will cover Wegovy for CV risk reduction in this population (separate from the anti-obesity statutory exclusion), which changes the coverage map dramatically.
  3. Insurance plan change that adds Wegovy coverage for chronic weight management. A 2026 employer-plan change or a switch to an exchange plan with broader anti-obesity-medication coverage can make the on-label option newly accessible at lower out-of-pocket cost than continued off-label Ozempic.
  4. Compounded semaglutide pathway closure pushing back to branded. With the FDA semaglutide shortage formally resolved in February 2025, the broad 503A compounding pathway for cash-pay patients closed. Patients re-entering the branded market in 2026 should evaluate Wegovy as the default option for weight management, not Ozempic.
  5. Maintenance phase after substantial weight loss already achieved. Long-term maintenance of weight loss on semaglutide has been studied at 2.4 mg in the STEP-4 and STEP-5 extension designs; the 2.4 mg Wegovy dose is the studied maintenance dose, not the 2.0 mg Ozempic dose. Patients planning to stay on therapy long-term for weight maintenance generally benefit from migrating to the on-label maintenance protocol.

The mechanics of the switch are straightforward because the molecule is identical. There is no washout period. Standard practice is to match the current Ozempic dose to the closest Wegovy step (0.25 / 0.5 / 1.0 / 1.7 / 2.4 mg) and resume the titration ladder from there with a brief tolerability check at each new step. Patients already tolerating Ozempic 2.0 mg typically advance to Wegovy 2.4 mg after a 4-week period at 1.7 mg if their prescriber chooses a conservative step-up.

For broader alternatives across the GLP-1 category, including tirzepatide-class options (Zepbound, Mounjaro), see Wegovy alternatives in 2026.

Bottom line

  • FDA-approved indication matters. Ozempic is FDA-approved only for type 2 diabetes glycemic control and CV risk reduction in T2D + established CV disease. Using Ozempic for weight loss without T2D is off-label.
  • Off-label is legal — not unethical. Under 21 USC 396 and the corresponding practice-of-medicine doctrine for drugs, licensed prescribers may use FDA-approved drugs off-label within the standard of care. Manufacturers cannot promote off-label uses; that constraint does not bind the clinician.
  • Wegovy is the on-label equivalent. Same semaglutide molecule, dosed higher (2.4 mg vs 2.0 mg max), FDA-approved for chronic weight management since 2021 and for CV risk reduction in obesity + CV disease since 2024.
  • The STEP-1 14.9% magnitude is the Wegovy number, not the Ozempic number. STEP-1 tested 2.4 mg in adults without diabetes; the Ozempic 2.0 mg maximum dose has no comparable obesity pivotal trial.
  • SELECT extends the cardiovascular safety record into non-diabetic adults at a higher dose than the Ozempic ceiling, giving solid extrapolative footing for off-label use safety in the non-diabetic obese population.
  • Insurance + cost reality drive the off-label pattern. T2D coverage is broader than weight-management coverage; that drives off-label Ozempic prescribing more than any clinical consideration does.
  • Migrate to Wegovy when the situation supports it. Plateau at Ozempic max dose, new CV disease, new insurance coverage, or long-term maintenance intent are all clean clinical triggers to switch to the on-label option.

Frequently asked questions

References

  1. 1.Novo Nordisk Inc. OZEMPIC (semaglutide) injection, for subcutaneous use — US Prescribing Information, Section 1 Indications and Usage. Indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus, and to reduce the risk of major adverse cardiovascular events in adults with T2D and established cardiovascular disease. Not indicated for chronic weight management. DailyMed (FDA Approved Labeling). 2025. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=adec4fd2-6858-4c99-91d4-531f5f2a2d79
  2. 2.Novo Nordisk Inc. WEGOVY (semaglutide) injection, for subcutaneous use — US Prescribing Information, Section 1 Indications and Usage. Indicated for chronic weight management in adults with obesity (BMI ≥30) or overweight (BMI ≥27) with at least one weight-related comorbidity, and in pediatric patients aged 12+ with BMI at the 95th percentile or above for age and sex; also indicated to reduce the risk of major adverse cardiovascular events in adults with established CV disease and obesity or overweight. DailyMed (FDA Approved Labeling). 2025. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=ee06186f-2aa3-4990-a760-757579d8f77b
  3. 3.Wilding JPH, Batterham RL, Calanna S, Davies M, Van Gaal LF, Lingvay I, McGowan BM, Rosenstock J, Tran MTD, Wadden TA, Wharton S, Yokote K, Zeuthen N, Kushner RF; STEP 1 Study Group. Once-Weekly Semaglutide in Adults with Overweight or Obesity (STEP 1). Semaglutide 2.4 mg once weekly produced mean body-weight reduction of -14.9% vs -2.4% placebo at 68 weeks (treatment-regimen estimand). This is the pivotal Wegovy dose trial; the Ozempic 2.0 mg maximum dose has not been tested in a comparable obesity pivotal trial. N Engl J Med. 2021. PMID: 33567185.
  4. 4.Sorli C, Harashima SI, Tsoukas GM, Unger J, Karsbøl JD, Hansen T, Bain SC. Efficacy and safety of once-weekly semaglutide monotherapy versus placebo in patients with type 2 diabetes (SUSTAIN 1): a double-blind, randomised, placebo-controlled, parallel-group, multinational, multicentre phase 3a trial. Semaglutide 0.5 mg and 1.0 mg weekly in T2D produced mean HbA1c reductions of about -1.45% and -1.55% and weight reductions of -3.7 and -4.5 kg at 30 weeks. Foundational Ozempic-dose evidence in the on-label T2D population. Lancet Diabetes Endocrinol. 2017. PMID: 28110911.
  5. 5.Marso SP, Bain SC, Consoli A, Eliaschewitz FG, Jódar E, Leiter LA, Lingvay I, Rosenstock J, Seufert J, Warren ML, Woo V, Hansen O, Holst AG, Pettersson J, Vilsbøll T; SUSTAIN-6 Investigators. Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes (SUSTAIN-6). Once-weekly semaglutide reduced the primary composite of cardiovascular death, nonfatal MI, or nonfatal stroke (HR 0.74, 95% CI 0.58-0.95) over a median 2.1 years in adults with T2D at high CV risk. Foundational CV-outcomes evidence for the Ozempic label; this is what authorizes the Ozempic CV indication in T2D + established CV disease. N Engl J Med. 2016. PMID: 27633186.
  6. 6.Lincoff AM, Brown-Frandsen K, Colhoun HM, Deanfield J, Emerson SS, Esbjerg S, Hardt-Lindberg S, Hovingh GK, Kahn SE, Kushner RF, Lingvay I, Oral TK, Michelsen MM, Plutzky J, Tornøe CW, Ryan DH; SELECT Trial Investigators. Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes (SELECT). Semaglutide 2.4 mg once weekly produced a 20% relative reduction in MACE (HR 0.80, 95% CI 0.72-0.90, p<0.001) in 17,604 adults with established CV disease and overweight/obesity but without diabetes, over a median 39.8 months. This is the only large RCT extending semaglutide cardiovascular safety + efficacy into the non-diabetic obese population. N Engl J Med. 2023. PMID: 37952131.
  7. 7.Mailhac A, Pedersen L, Pottegård A, Søndergaard J, Mogensen T. Semaglutide (Ozempic®) Use in Denmark 2018 Through 2023 — User Trends and off-Label Prescribing for Weight Loss. National prescription-registry pharmacoepidemiology study documenting the share of Ozempic prescriptions written outside the FDA-approved T2D indication, with magnitude estimates by patient comorbidity profile and prescriber specialty. Clin Epidemiol. 2024. PMID: 38685990.
  8. 8.Castellana E, Budau PM, Chiappetta MR. Overview of Diabetes Medications: Traditional and New-Generation Agents and Their Off-Label Use for Weight Loss. Review of the regulatory and pharmacologic landscape for off-label use of T2D drugs (including semaglutide as Ozempic and tirzepatide as Mounjaro) for obesity, including the dose-equivalent question between Ozempic 2.0 mg and Wegovy 2.4 mg. J Pharm Technol. 2026. PMID: 41743493.
  9. 9.Schmitz SH, Aronne LJ. The Effective Use of Anti-obesity Medications. Clinical-practice review (Weill Cornell Medicine, the SURMOUNT-5 senior-author group) covering FDA-approved vs off-label use of GLP-1 receptor agonists for obesity, dose-response considerations, and the clinical rationale for switching off-label Ozempic to on-label Wegovy when the goal is weight management. Gastroenterol Clin North Am. 2023. PMID: 37919019.
  10. 10.United States Code. 21 USC §396 — Practice of Medicine. Section 396 of the Federal Food, Drug, and Cosmetic Act states that nothing in the Act limits or interferes with the authority of a healthcare practitioner to prescribe or administer any legally marketed device to a patient for any condition or disease within a legitimate healthcare practitioner-patient relationship. The corresponding doctrine for drugs is established practice law: the FDA regulates manufacturer marketing and labeling, not the practice of medicine. Cornell Legal Information Institute. 2024. https://www.law.cornell.edu/uscode/text/21/396

Important disclaimer. This article is educational information only — not medical advice and not a substitute for consultation with a licensed prescriber. Ozempic and Wegovy are prescription medications with boxed warnings and contraindications; every clinical decision involving either drug must be made with a licensed prescriber who has reviewed the full FDA prescribing information and the individual patient’s history. Every regulatory and clinical claim in this article is anchored to a primary source (DailyMed, PubMed, or US Code). Weight Loss Rankings does not prescribe, dispense, or endorse any specific medication or pharmacy.